Psilocybin Therapy for Depression in Bipolar II Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-28

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

NCT04433845

Treatment Resistant Depression

UNKNOWN PHASE2

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression

NCT06506019

Bipolar Depression

RECRUITING PHASE1

Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

NCT06943573

Bipolar II Depression

NOT_YET_RECRUITING PHASE3

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

NCT06706232

Bipolar II Disorder Depression, Bipolar Suicidality

RECRUITING PHASE2

Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram

NCT00562861

Bipolar Disorder Bipolar Depression

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary goal of this study is to examine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder (BD II). Fourteen participants, ages 18 to 70 with clinically diagnosed BD II with active depression, in active outpatient mental health treatment, and who meet all other inclusion and exclusion criteria at screening will be enrolled. After baseline assessments, participants will engage in preparatory visits with trained facilitators, followed by an initial drug administration of oral psilocybin,supervised by the facilitators and a clinician who will conduct safety monitoring throughout. Participants will complete assessment and integration sessions with the facilitators subsequently in order to help process the experience. Participants who tolerated the first dosage may be asked to complete a second psilocybin dosing session, involving the same preparation, procedures, integration, and supervision as the first. Primary outcome measures will assess safety, tolerability, and feasibility of study procedures. Efficacy will be measured by change in depression as measured by the MADRS three weeks after the final psilocybin administration. Exploratory outcome measures will assess changes in sleep, quality of life, and therapeutic engagement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar II Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Open-label, single-arm, pilot study

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Psilocybin therapy

Participants will receive one or two doses of psilocybin in a monitored setting approximately three weeks apart, with preparation sessions before and integration sessions after.

Group Type EXPERIMENTAL

Psilocybin therapy

Intervention Type DRUG

\- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Psilocybin therapy

\- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

4-phosphoryloxy-N,N-dimethyltryptamine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 70
* Comfortable speaking and writing in English
* Diagnosis of Bipolar Disorder II with current depression
* Have a care partner/support person available throughout the study
* Able to attend all in-person visits at UCSF as well as virtual visits
* Having tried at least one previous medication trials for their bipolar disorder, each lasting at 6 weeks or more.

Exclusion Criteria

* Current or previous diagnosis of Bipolar I Disorder
* History of schizophrenia spectrum or psychotic disorder
* Use of psychedelics within the past 6 months, including MDMA
* Current diagnosis of cancer
* Seizures that continue to the present
* Fear of blood or needles
* Regular use of medications that may have problematic interactions with psilocybin, including but not limited to antidepressants (Bupropion allowed), serotonin antagonists, some antipsychotics, dopamine agonists/antagonists, stimulants, opioids, and Lithium.
* A health condition that makes this study unsafe or unfeasible, determined by study physicians

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No